Hill-Rom (HRC) Receives Buy Rating from KeyCorp

Hill-Rom (NYSE:HRC)‘s stock had its “buy” rating reaffirmed by KeyCorp in a research report issued to clients and investors on Thursday. They currently have a $97.00 price objective on the medical technology company’s stock. KeyCorp’s target price suggests a potential upside of 10.09% from the stock’s previous close.

A number of other brokerages have also recently issued reports on HRC. Barclays reiterated a “buy” rating and issued a $100.00 price target on shares of Hill-Rom in a research note on Wednesday, January 10th. Zacks Investment Research cut shares of Hill-Rom from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Needham & Company LLC restated a “buy” rating and set a $105.00 target price (up previously from $90.00) on shares of Hill-Rom in a research note on Tuesday. Raymond James Financial upgraded shares of Hill-Rom from a “market perform” rating to an “outperform” rating and set a $94.00 target price on the stock in a research note on Wednesday, January 3rd. Finally, Morgan Stanley cut shares of Hill-Rom from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 2nd. They noted that the move was a valuation call. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $95.25.

Hill-Rom (HRC) opened at $88.11 on Thursday. The stock has a market cap of $5,790.00, a PE ratio of 44.28, a P/E/G ratio of 1.53 and a beta of 1.19. Hill-Rom has a one year low of $57.18 and a one year high of $88.91. The company has a debt-to-equity ratio of 1.55, a current ratio of 1.77 and a quick ratio of 1.34.

Hill-Rom (NYSE:HRC) last announced its quarterly earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.27 by $0.05. The company had revenue of $738.30 million for the quarter, compared to analysts’ expectations of $731.10 million. Hill-Rom had a net margin of 4.87% and a return on equity of 20.27%. Hill-Rom’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.18 EPS. analysts expect that Hill-Rom will post 4.37 earnings per share for the current year.

In other Hill-Rom news, CEO John J. Greisch sold 100,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $82.82, for a total transaction of $8,282,000.00. Following the transaction, the chief executive officer now owns 230,851 shares in the company, valued at approximately $19,119,079.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Paul Sherwood Johnson sold 1,000 shares of the company’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $82.99, for a total transaction of $82,990.00. Following the transaction, the senior vice president now owns 1,066 shares in the company, valued at approximately $88,467.34. The disclosure for this sale can be found here. Insiders have sold a total of 226,241 shares of company stock worth $18,708,644 in the last 90 days. Company insiders own 2.20% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of HRC. Koch Industries Inc. bought a new position in shares of Hill-Rom in the 2nd quarter worth approximately $1,007,000. Wells Fargo & Company MN lifted its stake in shares of Hill-Rom by 298.1% in the 3rd quarter. Wells Fargo & Company MN now owns 1,133,900 shares of the medical technology company’s stock worth $83,908,000 after purchasing an additional 849,050 shares during the period. Lord Abbett & CO. LLC lifted its stake in shares of Hill-Rom by 535.6% in the 2nd quarter. Lord Abbett & CO. LLC now owns 543,398 shares of the medical technology company’s stock worth $43,260,000 after purchasing an additional 457,898 shares during the period. American Century Companies Inc. lifted its stake in shares of Hill-Rom by 385.0% in the 3rd quarter. American Century Companies Inc. now owns 535,229 shares of the medical technology company’s stock worth $39,607,000 after purchasing an additional 424,870 shares during the period. Finally, Hood River Capital Management LLC bought a new position in shares of Hill-Rom in the 2nd quarter worth approximately $22,473,000. Institutional investors and hedge funds own 81.92% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Hill-Rom (HRC) Receives Buy Rating from KeyCorp” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.chaffeybreeze.com/2018/01/18/hill-rom-hrc-receives-buy-rating-from-keycorp.html.

About Hill-Rom

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Analyst Recommendations for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply